Summit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by Citigroup
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by equities research analysts at Citigroup from a “neutral” rating to a “buy” rating in a report issued on Wednesday, MarketBeat.com reports. The firm currently has a $35.00 target price on the stock, up from their prior target price of $23.00. Citigroup’s target price would indicate […]
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by equities research analysts at Citigroup from a “neutral” rating to a “buy” rating in a report issued on Wednesday, MarketBeat.com reports. The firm currently has a $35.00 target price on the stock, up from their prior target price of $23.00. Citigroup’s target price would indicate […]
